Pharming Group Exceeds Annual Targets with Revenue of $376 Million
The Dutch laboratory Pharming Group has released its unaudited preliminary results for the fiscal year 2025, reporting a revenue of approximately $376 million, according to the group's statement. This performance surpasses the revised range of $365 to $375 million announced in November 2025.
The total revenue for the group in 2025 stands at approximately $376 million, marking an increase of about 27% compared to 2024, the company states. This performance is attributed to the continuous growth of RUCONEST and the increasing demand for Joenja, primarily fueled by patient adoption in the United States and supported by ongoing geographic expansion. The operational expenses for the full year 2025 are expected to fall within the previously communicated range of $304 to $308 million, the group emphasizes. The complete financial results for the fourth quarter and full year 2025 will be published on March 12, 2026.
Upcoming Virtual Investor Day
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Pharming Group will host a virtual investor day on February 3, 2026, at 10 AM Eastern Time, which is 4 PM Central European Time, the company announces. The agenda will include a comprehensive update on the developing portfolio, including leniolisib in Phase II clinical trials for primary immunodeficiencies with immune dysregulation, including common variable immunodeficiency with immune dysregulation, as well as KL1333 in a pivotal clinical study named FALCON for mitochondrial diseases linked to mitochondrial DNA. The group will also present its financial forecasts for 2026, highlighting anticipated revenue drivers and expectations regarding operational expenses. The program will feature presentations from leading clinical experts discussing the evolving understanding of immune dysregulation in primary immunodeficiencies and the unmet needs in mitochondrial diseases linked to mitochondrial DNA.
CEO's Statement on 2025 Performance
Fabrice Chouraqui, CEO of Pharming, stated in the announcement that the company had a strong year in 2025, driven by robust demand for its commercial assets and renewed financial discipline. According to him, RUCONEST continued to grow in an increasingly competitive environment, while the adoption of Joenja accelerated with the rise in demand from American patients and international expansion. Entering the year 2026, the group remains focused on advancing its clinical programs for other primary immunodeficiencies with immune dysregulation and primary mitochondrial diseases, while supporting the continued growth of its commercial portfolio, he added. Additional registration information for the investor day will be made available on the group's website in the coming weeks.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: T3 2026
Key reported figures
Revenue: 117,6 millions de dollars
Quarterly revenue: 117,6 millions de dollars
Revenue growth: 21 %
Guidance from the release
Tightened 2026 total revenue guidance to between US$380 million and US$390 million from prior US$375 million to US$395 million
Risks mentioned
Joenja revenue growth was partly driven by temporary benefit from ordering patterns in other international markets
RUCONEST third quarter revenue includes an early seasonal increase in channel inventory at a single U.S. specialty pharmacy customer, following significant drawdowns earlier in the year
Napazimone (KL1333): enrollment in the pivotal FALCON trial now expected to complete in the first half of 2027 (about 145 of 180 subjects by end-2026), with topline results approximately one year after completion of enrollment
Opportunities identified
RUCONEST stabilization and continued recovery of demand in the US (third quarter revenue of about US$93.8 million, +14% year-on-year and +30% versus the second quarter of 2026)
Joenja strong growth driven by launches in Germany, Japan and continued penetration in the U.K.
Substantial growth potential for Joenja with estimated CVID with immune dysregulation prevalence of 39 patients per million vs 1.5 for APDS
Outlook / guidance
Expected revenue: 385 millions de dollars
Management commentary: Tightened 2026 total revenue guidance to between US$380 million and US$390 million (1% to 4% growth) from prior US$375 million to US$395 million (0% to 5% growth)
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
